Skip to main content
. 2016 Dec 9;8(2):55–70. doi: 10.1177/2040620716680548

Figure 1.

Figure 1.

Guideline of treatment for newly diagnosed multiple myeloma.

Modified with permission from Lonial and Nooka [Lonial and Nooka, 2016].

ASCT, autologous stem cell transplant; CR, complete response; CyBorD, bortezomib, cyclophosphamide, and dexamethasone; FLC, free light chains; IRd, ixazomib-lenalidomide-dexamethasone; KRd, carfilzomib-lenalidomide-dexamethasone; MP, melphalan and prednisone; MPT, melphalan, prednisone, and thalidomide; MRI, magnetic resonance imaging; Rd, lenalidomide-dexamethasone; RVd, lenalidomide, bortezomib, dexamethasone; Vd, bortezomib-dexamethasone; VGPR, very good partial response; VMP, bortezomib, melphalan, and prednisone; VRD, bortezomib-lenalidomide-dexamethasone; VTD, bortezomib-thalidomide-dexamethasone.